Tags

Type your tag names separated by a space and hit enter

Variability in the prescription of cholinesterase inhibitors and memantine.
Dement Geriatr Cogn Disord. 2009; 28(4):373-9.DG

Abstract

BACKGROUND/AIM

To estimate the prevalence of Alzheimer's disease (AD) treatment in Aragon (Spain), analyzing differences according to age, gender and health area.

METHODS

Retrospective study on AD treatment prevalence of cholinesterase inhibitors and memantine during 2005, using pharmaco-epidemiological data from prescription refunds transferred monthly from pharmacies to the Health Care Service.

RESULTS

Differences between health areas were considerable, with adjusted prescription rates between 121.6 and 248.6/100,000 individuals. Treatment rates for women doubled those of men in each health area. Variability was greater among men than women. Drug prescription distribution was also different between health areas.

CONCLUSION

Considerable variability in AD treatment has been detected. More consensus is needed to reduce variability in order to improve the quality of the pharmacotherapy for AD and assure equal treatment opportunities for every patient.

Authors+Show Affiliations

Pharmacy Service, Hospital Universitario Miguel Servet, Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain. isavillar@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19887800

Citation

Villar-Fernández, I, et al. "Variability in the Prescription of Cholinesterase Inhibitors and Memantine." Dementia and Geriatric Cognitive Disorders, vol. 28, no. 4, 2009, pp. 373-9.
Villar-Fernández I, Bjerrum L, Feja C, et al. Variability in the prescription of cholinesterase inhibitors and memantine. Dement Geriatr Cogn Disord. 2009;28(4):373-9.
Villar-Fernández, I., Bjerrum, L., Feja, C., & Rabanaque, M. J. (2009). Variability in the prescription of cholinesterase inhibitors and memantine. Dementia and Geriatric Cognitive Disorders, 28(4), 373-9. https://doi.org/10.1159/000253845
Villar-Fernández I, et al. Variability in the Prescription of Cholinesterase Inhibitors and Memantine. Dement Geriatr Cogn Disord. 2009;28(4):373-9. PubMed PMID: 19887800.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Variability in the prescription of cholinesterase inhibitors and memantine. AU - Villar-Fernández,I, AU - Bjerrum,L, AU - Feja,C, AU - Rabanaque,M J, Y1 - 2009/11/02/ PY - 2009/09/14/accepted PY - 2009/11/6/entrez PY - 2009/11/6/pubmed PY - 2010/1/27/medline SP - 373 EP - 9 JF - Dementia and geriatric cognitive disorders JO - Dement Geriatr Cogn Disord VL - 28 IS - 4 N2 - BACKGROUND/AIM: To estimate the prevalence of Alzheimer's disease (AD) treatment in Aragon (Spain), analyzing differences according to age, gender and health area. METHODS: Retrospective study on AD treatment prevalence of cholinesterase inhibitors and memantine during 2005, using pharmaco-epidemiological data from prescription refunds transferred monthly from pharmacies to the Health Care Service. RESULTS: Differences between health areas were considerable, with adjusted prescription rates between 121.6 and 248.6/100,000 individuals. Treatment rates for women doubled those of men in each health area. Variability was greater among men than women. Drug prescription distribution was also different between health areas. CONCLUSION: Considerable variability in AD treatment has been detected. More consensus is needed to reduce variability in order to improve the quality of the pharmacotherapy for AD and assure equal treatment opportunities for every patient. SN - 1421-9824 UR - https://www.unboundmedicine.com/medline/citation/19887800/Variability_in_the_prescription_of_cholinesterase_inhibitors_and_memantine_ L2 - https://www.karger.com?DOI=10.1159/000253845 DB - PRIME DP - Unbound Medicine ER -